双特异性单克隆抗体在治疗中的应用  

THE BISPECIFIC MONOCLONAL ANTIBODY IN THERAPEUTICS

作　　者：刘庆涛[1] 魏东[1] 臧丽[1] 潘志忠[1] 张乃生[1] 

机构地区：[1]吉林大学畜牧兽医学院,长春130062

出　　处：《中国兽医寄生虫病》2007年第4期34-38,共5页Chinese Journal of Veterinary Parasitology

基　　金：国家自然科学基金(C02030603)

摘　　要：双特异性抗体由于其独特的结构——两个不同抗原,引起研究机构广泛的重视。双特异性单克隆抗体有两个臂,研究者将治疗药物和针对疾病部位的特异目标分别放在两个臂上。治疗药物可以是药品、毒素、酶、DNA和放射性核素等。此外,双特异性单克隆抗体能使免疫效应细胞的细胞毒性作用于致病细胞或者诱导产生全身免疫应答。双特异性单克隆抗体从治疗来看,有很大的发展前景,这是由于:(1)最近重组DNA技术的重大突破;(2)人类基因组图谱工程的完成,提高了疾病的鉴别水平;(3)对人类免疫系统机制有了更好的了解。The bispecific monoclonal antibodies （BsMAb） have drawn considerable attention from the research community due to their unique structure against two different antigens. The two-armed structure of BsMAb was targeted a therapeutic agent on one arm while allowing the other to specifically target the disease site. The therapeutic agent can be a drug, toxin, enzyme, DNA, radionuclide, etc. Furthermore, BsMAb may redirect the cyto- toxicity of immune effector cells towards the diseased cell or induce a systemic immune response against the target. BsMAb holds great promise for numerous therapeutic needs in the light of： （ 1 ） recent breakthroughs in recombinant DNA technology, （2） the increased number of identified disease targets as the result of the completion of human genomic map project, and （3） a better understanding of the mechanism of human immune system.

关 键 词：双特异性单克隆抗体 放射免疫疗法 结合物 

分 类 号：Q785[生物学—分子生物学]